Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength

Journal of Neurochemistry

Volumn 109, Issue 4, 2009, Pages 1017-1030

  Lei, Gang ^a   Anastasio, Noelle C ^a   Fu, Yu ^a   Neugebauer, Volker ^a   Johnson, Kenneth M ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

D1 receptor; NMDA receptors; NR1; NR2B; Phencyclidine; Phosphoinositol 3 kinase; Schizophrenia; Src kinase

Indexed keywords

CASPASE 3; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PROTEIN TYROSINE KINASE; SERINE;

ANIMAL CELL; ARTICLE; BRAIN CELL; BRAIN SLICE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; FEMALE; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SYNAPSE; SYNAPTIC POTENTIAL;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE AGONISTS; ELECTROPHYSIOLOGY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; IMMUNOPRECIPITATION; MALE; MEMBRANE PROTEINS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PATCH-CLAMP TECHNIQUES; PHENANTHRIDINES; PHENCYCLIDINE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; STARTLE REACTION; SYNAPSES; TYROSINE;

ANIMALIA; RATTUS;

EID: 65749086693     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06030.x     Document Type: Article

References (60)

1. Adams S. M., de Rivero Vaccari J. C. Corriveau R. A. (2004) Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. J. Neurosci. 24, 9441 9450. (Pubitemid 39426180)
2. Anastasio N. C. Johnson K. M. (2008) Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups. Pharmacol. Biochem. Behav. 90, 569 577.
3. Bandyopadhyay S., Gonzalez-Islas C. Hablitz J. J. (2005) Dopamine enhances spatiotemporal spread of activity in rat prefrontal cortex. J. Neurophysiol. 93, 864 872.
4. du Bois T. M. Huang X. F. (2007) Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res. Rev. 53, 260 270. (Pubitemid 46177233)
5. Bortolato M., Aru G. N., Fa M. et al. (2005) Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle. Neuropsychopharmacology 30, 561 574. (Pubitemid 40271158)
6. Braff D. L., Geyer M. A. Swerdlow N. R. (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156, 234 258. (Pubitemid 32705488)
7. Braithwaite S. P., Adkisson M., Leung J., Nava A., Masterson B., Urfer R., Oksenberg D. Nikolich K. (2006) Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP). Eur. J. Neurosci. 23, 2847 2856. (Pubitemid 43882863)
8. Broberg B. V., Dias R., Glenthoj B. Y. Olsen C. K. (2008) Evaluation of a neurodevelopmental model of schizophrenia - early postnatal PCP treatment in attentional set-shifting. Behav. Brain Res. 190, 160 163.
9. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M. Carlsson M. L. (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237 260. (Pubitemid 32385889)
10. Cepeda C., Buchwald N. A. Levine M. S. (1993) Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl Acad. Sci. USA 90, 9576 9580. (Pubitemid 23315828)
11. Chen G., Greengard P. Yan Z. (2004) Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc. Natl Acad. Sci. USA 101, 2596 2600. (Pubitemid 38269356)
12. Cull-Candy S. G. Leszkiewicz D. N. (2004) Role of distinct NMDA receptor subtypes at central synapses. Sci. STKE 2004, re16.
13. Curzon P. Decker M. W. (1998) Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 129 146. (Pubitemid 28096433)
14. Dunah A. W. Standaert D. G. (2001) Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21, 5546 5558. (Pubitemid 32692153)
15. Dunah A. W., Sirianni A. C., Fienberg A. A., Bastia E., Schwarzschild M. A. Standaert D. G. (2004) Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol. Pharmacol. 65, 121 129. (Pubitemid 38113892)
16. Duncan G. E., Moy S. S., Lieberman J. A. Koller B. H. (2006) Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol. Biochem. Behav. 85, 481 491. (Pubitemid 46097058)
17. Elvevag B. Goldberg T. E. (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14, 1 21. (Pubitemid 32193047)
18. Emamian E. S., Karayiorgou M. Gogos J. A. (2004) Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J. Neurosci. 24, 1561 1564. (Pubitemid 38240950)
19. Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C. R., Jokel E. S., Fienberg A. A., Greengard P. Levine M. S. (2002) Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J. Neurophysiol. 88, 3010 3020. (Pubitemid 35448687)
20. Gao C. Wolf M. E. (2008) Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons. J. Neurochem. 106, 2489 2501.
21. Geyer M. A., Krebs-Thomson K., Braff D. L. Swerdlow N. R. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156, 117 154. (Pubitemid 32702206)
22. Gonzalez-Islas C. Hablitz J. J. (2003) Dopamine enhances EPSCs in layer II-III pyramidal neurons in rat prefrontal cortex. J. Neurosci. 23, 867 875. (Pubitemid 36206177)
23. Greengard P. (2001) The neurobiology of dopamine signaling. Biosci. Rep. 21, 247 269. (Pubitemid 34208249)
24. Groc L., Choquet D., Stephenson F. A., Verrier D., Manzoni O. J. Chavis P. (2007) NMDA receptor surface trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein Reelin. J. Neurosci. 27, 10165 10175. (Pubitemid 47450452)
25. Hallett P. J., Spoelgen R., Hyman B. T., Standaert D. G. Dunah A. W. (2006) Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J. Neurosci. 26, 4690 4700. (Pubitemid 44315370)
26. Hardingham G. E., Fukunaga Y. Bading H. (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405 414. (Pubitemid 34454245)
27. Heresco-Levy U., Ermilov M., Giltsinsky B., Lichtenstein M. Blander D. (1999) Treatment-resistant schizophrenia and staff rejection. Schizophr. Bull. 25, 457 465.
28. Ikonomidou C., Bosch F., Miksa M. et al. (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283, 70 74. (Pubitemid 29044848)
29. Ivanov A., Pellegrino C., Rama S., Dumalska I., Salyha Y., Ben-Ari Y. Medina I. (2006) Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J. Physiol. 572, 789 798.
30. Javitt D. C. (2001) Management of negative symptoms of schizophrenia. Curr Psychiatry Rep 3, 413 417.
31. de Jong I. E. van den Buuse M. (2006) SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats. Neuropharmacology 51, 438 446.
32. Kargieman L., Santana N., Mengod G., Celada P. Artigas F. (2007) Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc. Natl Acad. Sci. USA 104, 14843 14848. (Pubitemid 350003230)
33. Lee F. J., Xue S., Pei L. et al. (2002) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111, 219 230. (Pubitemid 35292442)
34. Lei G., Xia Y. Johnson K. M. (2008) The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology 33, 1343 1353.
35. McGhie A. Chapman J. (1961) Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 34, 103 116.
36. Monti B. Contestabile A. (2000) Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebellum. Eur. J. Neurosci. 12, 3117 3123.
37. 2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol. Pharmacol. 71, 1598 1609. (Pubitemid 47010913)
38. Nakazawa T., Komai S., Tezuka T., Hisatsune C., Umemori H., Semba K., Mishina M., Manabe T. Yamamoto T. (2001) Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 276, 693 699. (Pubitemid 32050862)
39. Neve K. A., Seamans J. K. Trantham-Davidson H. (2004) Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24, 165 205. (Pubitemid 39332216)
40. Olney J. W. Farber N. B. (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13, 335 345. (Pubitemid 26007689)
41. Olney J. W., Newcomer J. W. Farber N. B. (1999) NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33, 523 533.
42. Papadia S., Soriano F. X., Leveille F. et al. (2008) Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 11, 476 487.
43. Prybylowski K., Chang K., Sans N., Kan L., Vicini S. Wenthold R. J. (2005) The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 47, 845 857. (Pubitemid 41266951)
44. Salter M. W. Kalia L. V. (2004) Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 5, 317 328. (Pubitemid 38478658)
45. Scott D. B., Blanpied T. A., Swanson G. T., Zhang C. Ehlers M. D. (2001) An NMDA receptor ER retention signal regulated by phosphorylation and alternative splicing. J. Neurosci. 21, 3063 3072. (Pubitemid 32323488)
46. Seamans J. K., Durstewitz D., Christie B. R., Stevens C. F. Sejnowski T. J. (2001) Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc. Natl Acad. Sci. USA 98, 301 306. (Pubitemid 32095904)
47. Shim S. S., Hammonds M. D. Kee B. S. (2008) Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur. Arch. Psychiatry Clin. Neurosci. 258, 16 27.
48. Slikker Jr. W., Zou X., Hotchkiss C. E. et al. (2007) Ketamine-induced neuronal cell death in the perinatal rhesus monkey. Toxicol Sci 98, 145 158. (Pubitemid 47073827)
49. Snyder G. L., Fienberg A. A., Huganir R. L. Greengard P. (1998) A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18, 10297 10303. (Pubitemid 29016549)
50. Snyder E. M., Nong Y., Almeida C. G. et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 1051 1058. (Pubitemid 41061516)
51. Soriano F. X., Papadia S., Hofmann F., Hardingham N. R., Bading H. Hardingham G. E. (2006) Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J. Neurosci. 26, 4509 4518. (Pubitemid 44315350)
52. Sun X., Zhao Y. Wolf M. E. (2005) Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J. Neurosci. 25, 7342 7351. (Pubitemid 41129806)
53. Suzuki T. Okumura-Noji K. (1995) NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem. Biophys. Res. Commun. 216, 582 588.
54. Tingley W. G., Ehlers M. D., Kameyama K., Doherty C., Ptak J. B., Riley C. T. Huganir R. L. (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272, 5157 5166. (Pubitemid 27090073)
55. Tseng K. Y. O'Donnell P. (2004) Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 24, 5131 5139. (Pubitemid 38728985)
56. Wang C. Z. Johnson K. M. (2007) The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 32, 1178 1194. (Pubitemid 46631972)
57. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J. L. Johnson K. M. (2001) Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107, 535 550. (Pubitemid 33097492)
58. Williams G. V. Goldman-Rakic P. S. (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572 575.
59. 2+. Hippocampus 10, 57 63. (Pubitemid 30107590)
60. Yang C. R. Chen L. (2005) Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 11, 452 470. (Pubitemid 41339230)